文献速递免疫规划传染病防控与疫情报告

EV-A71灭活疫苗(人二倍体细胞)上市后安全性观察

[Post-marketing observation on safety of inactivated enterovirus A71 vaccine (human diploid cell)].
PubMed 文献 · Zhonghua Yu Fang Yi Xue Za Zhi · 2019-01-01

第1剂和第2剂不良反应发生率分别为2.045%和1.611%,以全身不良反应为主,局部反应轻微,总体预后良好。

要点

  • 第1剂和第2剂3天内不良反应发生率分别为2.045%和1.611%。
  • 局部反应多轻微,全身反应中3级及以上发热占发热总数的8.2%。

核心结论

  • 儿童接种EV-A71疫苗后3天内不良反应发生率较低,主要为全身不良反应,且预后良好。

研究设计与样本

  • 每剂接种后第4或5天电话随访监护人,记录接种后3天内局部、全身和其他不良反应。

主要发现

  • 第1剂和第2剂3天内不良反应发生率分别为2.045%(413剂次)和1.611%(194剂次)。
  • 第1剂和第2剂全身不良反应发生率分别为1.837%(371剂次)和1.454%(175剂次)。
  • 第1剂和第2剂局部不良反应发生率分别为0.069%(14剂次)和0.017%(2剂次)。
  • 局部不良反应仅2例为3级;全身不良反应中3级及以上发热39例,占总发热例数的8.2%。
  • 局部不良反应仅3例接种部位皮疹和2例瘙痒需自购药或门诊治疗;全身不良反应除5例发热外均未住院。

临床怎么用

  • 为6~59月龄儿童接种EV-A71疫苗的安全性提供了上市后数据,接种后3天内以全身反应为主且多可自行缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the post-marketing safety of inactivated Enterovirus type 71 (EV-A71) vaccine (human diploid cell) . Methods: A total of 20 191 healthy children aged 6 to 59 months were invited to receive 2 doses of EV-A71 vaccine in Zhejiang Province from September 2016 to December 2017. Child caregivers were followed up on the 4(th) or 5(th) day after each EV-A71 vaccination, and the incidence of local, systemic, and other adverse events within 3 days after vaccination was recorded to assess vaccine safety. Describe the differences in adverse events among children with different characteristics. Results: A total of 32 230 doses were observed in this study, of which 20 191 and 12 039 were vaccinated for the first and the second dose, respectively; and the incidence of adverse events within 3 days was 2.045% (413 doses) and 1.611% (194 doses), respectively. After the first and the second dose, the number of systemic adverse events was the highest, 371 and 175 cases, respectively, with an incidence of 1.837% and 1.454%, respectively; the number of local adverse events was the lowest, 14 and 2 doses, respectively, with an incidence of 0.069% and 0.017%. Local adverse events occurred after vaccination were generally mild, and only 2 patients had level of 3; among the systemic adverse events, 39 patients had a fever level of 3 or higher, accounting for 8.2% of the total fever. Most of the symptoms in the local adverse events did not require treatment, only 3 cases of vaccination site rash and 2 cases of pruritus were self-purchased drugs or outpatient treatment; except for 5 cases of fever, the other symptoms were not hospitalized in the case of systemic adverse events. Conclusion: The incidence of adverse events within 3 days after vaccination with EV-A71 vaccine was low in children, mainly systemic adverse events, and the prognosis was good. 目的: 评价肠道病毒A71型(EV-A71)灭活疫苗(EV-A71疫苗)(人二倍体细胞)上市后接种的安全性。 方法: 以2016年9月至2017年12月在浙江省预防接种门诊接种EV-A71疫苗的6~59月龄健康儿童作为研究对象,共20 191名。在每剂EV-A71疫苗接种后第4或5天对儿童监护人进行电话随访,记录儿童接种后3 d内局部、全身和其他不良反应发生情况,描述不同特征儿童不良反应发生情况。 结果: 共接种疫苗32 230剂次,第1和2剂分别为20 191和12 039剂次,3 d内不良反应发生率分别为2.045%(413剂次)和1.611%(194剂次)。第1和2剂全身不良反应剂次均较多,分别为371和175剂次,发生率分别为1.837%和1.454%;局部不良反应剂次均较低,分别为14和2剂次,发生率分别为0.069%和0.017%。接种后发生的局部不良反应一般症状轻微,出现3级不良反应病例仅2例;全身不良反应中,3级及以上发热病例为39例,占总发热例数的8.2%。局部不良反应中,仅有3例接种部位皮疹和2例瘙痒病例需自购药或门诊治疗,其余无需治疗;全身不良反应中,除5例发热病例外,其余症状均未住院治疗。 结论: 儿童接种EV-A71疫苗后3 d内不良反应发生率较低,主要为全身不良反应,且预后良好。.

来源:Zhonghua Yu Fang Yi Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Shen LZ, Fu J, Pan XJ, et al. [Post-marketing observation on safety of inactivated enterovirus A71 vaccine (human diploid cell)]. Zhonghua Yu Fang Yi Xue Za Zhi. 2019. PMID: 30841663. doi:10.3760/cma.j.issn.0253-9624.2019.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。